| From: chowder | 5/6/2021 1:29:14 PM | | | | | | If anyone has an interest in SQ, they announce earnings after the market close today. If their report is anything like PYPL's was, it's possible SQ will show a nice pop in price. This is one example of where I will sometimes front run an earnings report as opposed to waiting post announcement.
SQ is down 3.57% as I type. I could be wrong but I'm thinking it will take a terrible report to cause price to dip much further. An earnings surprise to the upside though might cause price to have a nice pop tomorrow.
Again, this just an opinion but it is an example of how I play earnings announcements. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: chowder | 5/6/2021 4:23:52 PM | | | | | | Square EPS beats by $0.25, beats on revenue
May 06, 2021 4:13 PM ET Square, Inc. (SQ) By: Gaurav Batavia, SA News Editor 8 Comments
Square (NYSE: SQ): Q1 Non-GAAP EPS of $0.41 beats by $0.25; GAAP EPS of $0.08 beats by $0.14.
Revenue of $5.06B (+266.7% Y/Y) beats by $1.73B.In the first quarter of 2021, mid-market Seller GPV increased 43% year over year, more than 2x the growth of total Seller GPV.
Okay, now we'll see what sort of follow through we have. It was down 3.5% at the time of my comment, went down to 7% later in the session. Let's see where it opens tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: chowder who wrote (290) | 5/6/2021 5:12:21 PM | | From: inspbudget | | | | The general mood of growth stocks and the NASDAQ overall has been ugly the past couple weeks.
I hope that the Stock Price will improve, but looking at after hours action, would not be altogether surprised if it drops tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Frank Sully | 5/6/2021 11:18:35 PM | | | | | | Global CRISPR and CAS Gene Market to Surpass US$ 3,494.4 Million by 2027, Says Coherent Market Insights (CMI)
Wed, May 5, 2021, 10:00 AM
According to Coherent Market Insights, the global CRISPR and CAS gene market is estimated to be valued at US$ 830.7 million in 2020 and is expected to exhibit a CAGR of 22.8% during the forecast period (2020-2027).
Key Trends and Analysis of the Global CRISPR and CAS Gene Market:
Key trends in the market include increasing research and development activities, product launches, inorganic activities such as collaborations, and others.
Key players are focusing on increasing research and development for new treatments for genetic disorders, which is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, in June 2019, GlaxoSmithKline Plc partnered with gene-editing pioneers based at the University of California (UC) to establish a new laboratory that aims to speed up discovery of new treatments by exploring how gene mutations cause disease, and developing new CRISPR-based technologies.
Market players are indulged in launching new kits, which is expected to drive growth of the market over the forecast period. For instance, in June 2019, Synthego, a global genome engineering solutions company, announced the launch of the Gene Knockout Kit v2. This is the only product that leverages a novel bioinformatics- powered multi-guide strategy to guarantee a gene knockout. The kit will accelerate research by saving scientists from multiple trial-and-error cycles in optimizing their CRISPR experiment.
Various biotechnology and pharmaceutical companies are focusing on collaborations to conduct research and development for treatment of diseases such as cancer, AIDS, genetic diseases, and others, which is expected to drive growth of the market. For instance, in October 2019, CRISPR Therapeutics and Bayer announced plans for a joint venture between CRISPR Therapeutics and Bayer and Casebia Therapeutics would operate under the direct management of CRISPR Therapeutics. Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology, and autoimmune diseases.
Key Market Takeaways:
Increasing prevalence of genetic disorders such as Down’s syndrome, Sickle cell anemia, and Huntington’s disease worldwide is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, according to National Health Service (NHS) U.K., 2018 report, the highest rate of Huntington’s disease in the U.K. is 12 per 100,000 people.
Among all the regions, North America is expected to hold a dominant position in the global CRISPR and CAS gene market over the forecast period, owing to the increasing number of research studies regarding the CRISPR and CAS gene technology in the region. For instance, in 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR. Under the terms of the agreement, Juno had to pay Editas an initial payment of US$ 25 million, in which up to US$ 22 million will be used in research support for three programs over five years.
Competitive Landscape:
Key players operating in the global CRISPR and CAS gene market include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: 2hugo who wrote (294) | 5/7/2021 4:14:58 AM | | From: chowder | | | | >> Have you been adding/reducing to disruptive stocks besides crypto in any of your portfolios young/old folk?
Crypto only. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (289) | 5/7/2021 3:50:26 PM | | From: chowder | | | | I commented yesterday that SQ was set up as an example of how I like to front run an earnings report. At the time it was down 3.5%, dropped as low as 7% and is currently up today at 4% after a stellar earnings report.
I wish all purchases were this easy.
The catalyst was the PYPL earnings report and the positive reaction the market had to it. I assumed SQ would have similar results and they did not disappoint. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (279) | 5/8/2021 9:40:23 AM | | From: Cogito Ergo Sum | | | | | Well I have collision avoidance on my 2018 Coloarado.. but also lane divergence .. I got to tell you I am impressed .. even in snowy conditions it is pretty awesome.. I learned to drive in chitty QC weather.. have a good feel for where the road is in bad chit.. but this stuff works great.. it has been bang on even in snowy roads.. I do not know that the tech is .. guess I should check.. but it is great.. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
